Real-world burden of cardiovascular events following immune checkpoint inhibitor therapy: impact on mortality and treatment resumption in 29,503 patients

Lung Cancer · Published 2026-06-14 · DOI 10.1016/j.lungcan.2026.109499

Authors (4)

Clemence Rigaux, Dimitri Arangalage, Karissa Adkins, Stephane Illiano

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Rigaux, C., Arangalage, D., Adkins, K., et al. (2026). Real-world burden of cardiovascular events following immune checkpoint inhibitor therapy: impact on mortality and treatment resumption in 29,503 patients. Lung Cancer. https://doi.org/10.1016/j.lungcan.2026.109499

Related articles

• Epiproteomic profiling identifies histone H4 hyperacetylation as a prognostic marker in pleural mesothelioma · Lung Cancer · 2026 · Same journal
• Neoadjuvant and perioperative chemo-immunotherapy in early-stage non-small cell lung cancer: international expert panel meeting by AIOT · Lung Cancer · 2026 · Same journal
• BRAF fusions define therapeutic vulnerability and tyrosine kinase inhibitor resistance in non-small cell lung cancer · Lung Cancer · 2026 · Same journal
• Biology, detection, and management of incidental pulmonary nodules: the emerging role of targeted treatments. A review of the current literature and future perspectives · Lung Cancer · 2026 · Same journal
• Efficacy and safety of immune checkpoint inhibitors in lung cancer patients with hepatitis B surface antigen positivity: a real-world cohort study · Lung Cancer · 2026 · Same journal
• Time-dependent bias in local consolidative therapy for EGFR-mutant metastatic non-small cell lung cancer · Lung Cancer · 2026 · Same journal
• Clonal divergence with acquired BRAF V600E in NSCLC with compound EGFR G719X/S768I after prolonged EGFR-TKI therapy · Lung Cancer · 2026 · Same journal
• CT surveillance, patterns of recurrence and eligibility for salvage therapy after curative intent treatment for unresectable stage III non small cell lung cancer · Lung Cancer · 2026 · Same journal
• First-line treatment for unresectable pulmonary lymphoepithelial carcinoma: A real-world comparison of platinum-based doublet chemotherapy with or without PD-1 inhibitors · Lung Cancer · 2026 · Same journal
• Development and validation of a risk-stratification model for individualized management of leptomeningeal metastases in EGFR- mutant NSCLC (LM-Index) · Lung Cancer · 2026 · Same journal